Pasar al contenido principal

FARMACOS INNOVADORES PARA ENFERMEDADES NEURODEGENERATIVAS (ALZHEIMER Y ESCLEROSIS LATERAL AMIOTROFICA) ACTIVOS EN DIANAS NEUROGENICAS Y NEUROPROTECTORAS

SAF2015-64948-C2-1-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Neurogenic inducers based on the chromone scaffold, a new family of multitarget directed ligands for Alzheimer's disease

  • Estrada, Martín
  • Herrera-Arozamena, Clara
  • Andrés, Lucía de
  • Pérez, Concepción
  • Morales-García, José A.
  • Pérez Castillo, Ana
  • Romero Jódar, Alejandro
  • Viña, Dolores
  • Pricl, Sabrina
  • Laurini, E.
  • Rodríguez-Franco, María Isabel
Resumen del trabajo presentado a la XXXVIII Reunión Anual del Grupo Español de Neurotransmisión y Neuroprotección (GENN), celebrada en Almagro (Ciudad Real) del 13 al 15 de diciembre de 2017., The highly complex pathophysiology of Alzheimer's disease (AD) and other neurodegenerative illnesses have led to replace the traditional one-drug - one-target by the multi-target-directed ligands (MTDLs) paradigm, in which a single molecule is designed to be active against several pharmacological targets. Continuing with our interest in neuroprotective and neurogenic compounds, in this work we describe a new family of donepezil flavonoid hybrids exhibiting nanomolar affinities for the sigma-1 receptor and a combined inhibition of key enzymes in AD, such as 5-lipoxygenase, acetylcholinesterase, and monoaminoxidases. In general, they scavenge free radical species and are predicted to be brain-permeable. In phenotypic assays, new hybrids protect neuronal cells against mitochondrial oxidative stress and promote maturation of neural stem cells into a neuronal phenotype. Therefore, new donepezil - flavonoid hybrids could contribute to the protection and even, the reparation of neuronal tissues, of great therapeutic interest in AD and neurodegenerative diseases., Spanish Ministry of Economy and Competitiveness MINECO (grant SAF2015-64948-C2-1-R) and Spanish National Research Council CSIC (grant PIE-201580E109)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Synthesis of 3-indolyltriazoles via Sonogashira coupling and azide-alkyne cycloaddition promoted by supported copper nanoparticles

  • Stabile, S.
  • Vitale, C. A.
  • Rodríguez-Franco, María Isabel
In this work we present the synthesis of a novel series of 3-indolyl-1,4-disubstituted 1,2,3-triazoles. The key steps in the synthetic route are shown in Scheme 1. A series of N-protected 3-iodoindoles were subjected to a Sonogashira cross-coupling reaction with trimethylsilylacetylene in presence of PdCl2(PPh)3 and CuI as catalysts and TEA as base, following the procedures described by Boger [1]. After deprotection of the silyl group, 1,2,3-triazoles were obtained through the azide-alkyne Huisgen 1,3-dipolar cycloaddition catalysed by copper nanoparticles (CuNPs) immobilized on activated carbon, which were prepared using the CuCl2-Li-4,4¿-Di-tert-butylbiphenyl (DTBB) reducing system previously reported by our group [2]., This work was performed in the Instituto de Química Médica (IQM-CSIC) with grants from the following agencies: Dirección General de Investigación e Innovación de la Comunidad de Madrid y Fondo Europeo de Desarrollo Regional (B2017/BMD-3827); Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación y FEDER (SAF2015-64948-C2-1-R and RTI2018-093955-B-C21); Universidad Nacional del Sur, programa de Pasantías en Centros de Investigación destinada a Jóvenes Docentes.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Surface plasmon resonance for the discovery of new non-electrophilic inhibitors of KEAP1-NRF2 protein-protein interaction

  • Estrada-Valencia, M.
  • Herrera-Arozamena, Clara
  • Lagartera, Laura
  • Cuadrado, Antonio
  • Fernández-Ginés, Raquel
  • García-Yagüe, Ángel Juan
  • Morales-García, J. A.
  • Pérez-Castillo, Amalia
  • Rodríguez-Franco, María Isabel
In recent years the nuclear transcription factor (erythroid-derived 2)¿like 2 (Nrf2) has been identified as the key factor in the cell auto-protection mechanisms. Under no pathological conditions, Nrf2 is mainly located in the cytosol, bound to the Kelch like ECH associated protein 1 (Keap1). In contrast, under oxidative conditions, Keap1 changes its conformation and breaks the binding with Nrf2 allowing its accumulation and translocation to the nucleus where it induces the transcription of key antioxidant enzymes. Nrf2 dysregulation is involved in different pathologies such as cancer, cardiovascular diseases or neurodegenerative diseases, among others [1]. In recent years, a great amount of new molecules able to disrupt the interaction between Nrf2 and Keap1, have been studied, however most of them are electrophilic molecules and are prone to interact with several non-desired targets. In our group we are applying the surface plasmon resonance (SPR) technique for the identification of new non-electrophilic inhibitors of the Nrf2 - Keap1 protein-protein interaction (PPI). This kind of molecules could exhibit a more specific mechanism for the induction of Nrf2 activity. Thus, the ability of several molecules from our library to interact with the purified Kelch domain of Keap1 attached to a CM5 sensor chip has been evaluated in a SPR assay [2]. With this technique, a new hit with affinity for Keap1 was identified. The affinity value was comparable to that of the positive control ML-334, a well-known inhibitor of the Nrf2 - Keap1 PPI. Starting from this new hit, a larger family with improved potency have been obtained [3]. This new family of bis-heterocyclic compounds do not present any electrophilic character, are able to reach the central nervous system and exhibit other complementary activities such as radical scavenging and neurogenic properties, which make them potential candidates for the treatment of neurodegenerative diseases such as Alzheimer¿s disease., Dirección General de Investigación e Innovación de la Comunidad de Madrid y Fondo Europeo de Desarrollo Regional (B2017/BMD-3827, NRD24AD-CM); Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación y FEDER (SAF2015-64948-C2-1-R, RTI2018-093955-B-C21
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Lewis acid-catalysed oligomerization of methoxy- or ciano-indoles: synthesis of potential biologically active compounds

  • Sempere-Pérez, I.
  • Estrada-Valencia, M.
  • Rodríguez-Franco, María Isabel
Compounds containing the indole nucleus show an extensive assortment of biological and pharmacological activities, including analgesic, antiallergic, antibacterial, anti-HIV, antitumor, and antioxidant properties [1,2]. Recently, the synthesis and anticancer properties of alkaloids with dimeric indole scaffolds were reported [3]. Therefore, our interest was focused on the study of the oligomerization reactions of 4-, 6- and 7- substituted indoles with electron donor groups, i.e. methoxy group, and electron withdrawing groups, i.e. nitrile group, using a Lewis acid (bismuth chloride). From our results, we concluded that indole oligomerization is sensitive to the substituent on the heterocycle. Both the substituent position and the inductive effects of the substituents, determine which products and in which ratio they are formed. We were also able to propose possible mechanisms for the reaction that can explain the different products obtained for each substrate. ., Dirección General de Investigación e Innovación de la Comunidad de Madrid y Fondo Europeo de Desarrollo Regional (B2017/BMD-3827); Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación y FEDER (SAF2015-64948-C2-1-R and RTI2018-093955-B-C21); Consejo Superior de Investigaciones Científicas (JAE-Intro18_EX-0264 a I.S.-P.)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

New neurogenic inducers with combined activities in key targets related to Alzheimer¿s disease

  • Herrera-Arozamena, Clara
  • Estrada-Valencia, M.
  • Pérez, Concepción
  • Viña, D.
  • Michalska, Patrycja
  • León, Rafael
  • López, M. G.
  • Morales-García, J. A.
  • Pérez-Castillo, Amalia
  • Rodríguez-Franco, María Isabel
Alzheimer¿s Disease (AD) is a complex multifactorial illness with no effective cure, characterized by the irreversible memory loss and global cognitive impairment. Given that the marketed drugs act only at one single target, being a symptomatic treatment, exploration of new molecules acting in different pathways is required. In this sense, we have developed a large family of multitarget directed ligands (MTDL), which interacts in different targets related to neurodegeneration, such as the nuclear factor (erythroid-derived 2)-like 2 (Nrf2), lipoxygenase-5 (LOX-5), melatonin receptors (MT1, MT2, and MT3), and monoamine oxidases (MAO-A and MAO-B). The affinity or inhibition constants of these compounds in such targets are in the nanomolar and micromolar ranges. In general, these molecules have potent antioxidant properties (ORAC assay) and are able to penetrate into the central nervous system (CNS) by passive diffusion (PAMPA-BBB assay). Moreover, some of them are able to promote neurogenesis in vitro by inducing the maturation of neural stem cells into a neuronal phenotype. A structure-activity relationship has been stablished, reaching an optimized structure as possible candidate to treat AD, able to cross the blood brain barrier, reaching the CNS where it would act in three targets involved in the regulation of oxidative stress, as Nrf2 inducer, MT3 ligand and selective MAO B inhibitor. Furthermore, this MTDL is an effective neuroprotective and neurogenic agent., Dirección General de Investigación e Innovación de la Comunidad de Madrid y Fondo Europeo de Desarrollo Regional (B2017/BMD-3827); Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación y FEDER (SAF2015-64948-C2-1-R and RTI2018-093955-B-C21). C.H.-A. thanks Spanish Ministry of Education for a FPU fellowship (grant FPU16/01704)